De Novo prograf versus de Novo Advagraf

Are trough level profile curves similar?

E. Sárváry, L. Wágner, G. Telkes, Gy Gaman, M. Varga, I. Gaal, Zs Mathe, R. Chmel, I. Fehervari, R. Langer

Research output: Contribution to journalArticle

Abstract

Background. According to the clinical trials, Advagraf (ADV) has efficacy and safety profile similar to Prograf (PROG). The aim of this study was to compare the graft functions, dosages, and tacrolimus (TAC) trough level profile curves of patients on de novo PROG and ADV therapy. Methods. The ADV group included 39 de novo renal cases who had received initial immunosuppression (IS) with once-daily TAC (1 × 0.2 mg/kg from day1 after transplantation). We compared them with a PROG group of 38 transplant patients who received equivalent IS with twice-daily TAC (2 × 0.1 mg/kg from day1). In both groups, the IS was combined with antimetabolites and steroids. The mean follow-up time was similar (13.5 ± 7 days) in both groups after renal transplantation until the emission of the patients from our clinic. Results. TAC mean total daily dose was reduced and whole-blood trough levels decreased over the time in early postoperative days. Only on day 3 and day 4 after transplant, a significant higher adjustment in the ADV dosage was necessary to achieve sufficient TAC trough levels. The average TAC trough level profile curves were similar in PROG and ADV groups, but the individual curves were very different. Mainly in patients on ADV therapy, the initial concentrations were often >30 ng/mL, and in some cases on the 9th posttransplant day decreased to

Original languageEnglish
Pages (from-to)2164-2167
Number of pages4
JournalTransplantation Proceedings
Volume46
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Tacrolimus
Immunosuppression
Transplants
Antimetabolites
Kidney Transplantation
Transplantation
Steroids
Clinical Trials
Kidney
Safety

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Medicine(all)

Cite this

De Novo prograf versus de Novo Advagraf : Are trough level profile curves similar? / Sárváry, E.; Wágner, L.; Telkes, G.; Gaman, Gy; Varga, M.; Gaal, I.; Mathe, Zs; Chmel, R.; Fehervari, I.; Langer, R.

In: Transplantation Proceedings, Vol. 46, No. 6, 2014, p. 2164-2167.

Research output: Contribution to journalArticle

Sárváry, E. ; Wágner, L. ; Telkes, G. ; Gaman, Gy ; Varga, M. ; Gaal, I. ; Mathe, Zs ; Chmel, R. ; Fehervari, I. ; Langer, R. / De Novo prograf versus de Novo Advagraf : Are trough level profile curves similar?. In: Transplantation Proceedings. 2014 ; Vol. 46, No. 6. pp. 2164-2167.
@article{8773d00628104207bddddd3e0d13f552,
title = "De Novo prograf versus de Novo Advagraf: Are trough level profile curves similar?",
abstract = "Background. According to the clinical trials, Advagraf (ADV) has efficacy and safety profile similar to Prograf (PROG). The aim of this study was to compare the graft functions, dosages, and tacrolimus (TAC) trough level profile curves of patients on de novo PROG and ADV therapy. Methods. The ADV group included 39 de novo renal cases who had received initial immunosuppression (IS) with once-daily TAC (1 × 0.2 mg/kg from day1 after transplantation). We compared them with a PROG group of 38 transplant patients who received equivalent IS with twice-daily TAC (2 × 0.1 mg/kg from day1). In both groups, the IS was combined with antimetabolites and steroids. The mean follow-up time was similar (13.5 ± 7 days) in both groups after renal transplantation until the emission of the patients from our clinic. Results. TAC mean total daily dose was reduced and whole-blood trough levels decreased over the time in early postoperative days. Only on day 3 and day 4 after transplant, a significant higher adjustment in the ADV dosage was necessary to achieve sufficient TAC trough levels. The average TAC trough level profile curves were similar in PROG and ADV groups, but the individual curves were very different. Mainly in patients on ADV therapy, the initial concentrations were often >30 ng/mL, and in some cases on the 9th posttransplant day decreased to",
author = "E. S{\'a}rv{\'a}ry and L. W{\'a}gner and G. Telkes and Gy Gaman and M. Varga and I. Gaal and Zs Mathe and R. Chmel and I. Fehervari and R. Langer",
year = "2014",
doi = "10.1016/j.transproceed.2014.05.061",
language = "English",
volume = "46",
pages = "2164--2167",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - De Novo prograf versus de Novo Advagraf

T2 - Are trough level profile curves similar?

AU - Sárváry, E.

AU - Wágner, L.

AU - Telkes, G.

AU - Gaman, Gy

AU - Varga, M.

AU - Gaal, I.

AU - Mathe, Zs

AU - Chmel, R.

AU - Fehervari, I.

AU - Langer, R.

PY - 2014

Y1 - 2014

N2 - Background. According to the clinical trials, Advagraf (ADV) has efficacy and safety profile similar to Prograf (PROG). The aim of this study was to compare the graft functions, dosages, and tacrolimus (TAC) trough level profile curves of patients on de novo PROG and ADV therapy. Methods. The ADV group included 39 de novo renal cases who had received initial immunosuppression (IS) with once-daily TAC (1 × 0.2 mg/kg from day1 after transplantation). We compared them with a PROG group of 38 transplant patients who received equivalent IS with twice-daily TAC (2 × 0.1 mg/kg from day1). In both groups, the IS was combined with antimetabolites and steroids. The mean follow-up time was similar (13.5 ± 7 days) in both groups after renal transplantation until the emission of the patients from our clinic. Results. TAC mean total daily dose was reduced and whole-blood trough levels decreased over the time in early postoperative days. Only on day 3 and day 4 after transplant, a significant higher adjustment in the ADV dosage was necessary to achieve sufficient TAC trough levels. The average TAC trough level profile curves were similar in PROG and ADV groups, but the individual curves were very different. Mainly in patients on ADV therapy, the initial concentrations were often >30 ng/mL, and in some cases on the 9th posttransplant day decreased to

AB - Background. According to the clinical trials, Advagraf (ADV) has efficacy and safety profile similar to Prograf (PROG). The aim of this study was to compare the graft functions, dosages, and tacrolimus (TAC) trough level profile curves of patients on de novo PROG and ADV therapy. Methods. The ADV group included 39 de novo renal cases who had received initial immunosuppression (IS) with once-daily TAC (1 × 0.2 mg/kg from day1 after transplantation). We compared them with a PROG group of 38 transplant patients who received equivalent IS with twice-daily TAC (2 × 0.1 mg/kg from day1). In both groups, the IS was combined with antimetabolites and steroids. The mean follow-up time was similar (13.5 ± 7 days) in both groups after renal transplantation until the emission of the patients from our clinic. Results. TAC mean total daily dose was reduced and whole-blood trough levels decreased over the time in early postoperative days. Only on day 3 and day 4 after transplant, a significant higher adjustment in the ADV dosage was necessary to achieve sufficient TAC trough levels. The average TAC trough level profile curves were similar in PROG and ADV groups, but the individual curves were very different. Mainly in patients on ADV therapy, the initial concentrations were often >30 ng/mL, and in some cases on the 9th posttransplant day decreased to

UR - http://www.scopus.com/inward/record.url?scp=84906077393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906077393&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2014.05.061

DO - 10.1016/j.transproceed.2014.05.061

M3 - Article

VL - 46

SP - 2164

EP - 2167

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -